This company has been marked as potentially delisted and may not be actively trading. NYSE:CBM Cambrex (CBM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cambrex Stock (NYSE:CBM) 30 days 90 days 365 days Advanced Chart Remove Ads Get Cambrex alerts:Sign Up Key Stats Today's Range$59.99▼$59.9950-Day Range$59.99▼$59.9952-Week Range$33.80▼$60.29VolumeN/AAverage Volume218,726 shsMarket Capitalization$2.02 billionP/E Ratio21.66Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.Read More… Remove Ads Receive CBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cambrex and its competitors with MarketBeat's FREE daily newsletter. Email Address CBM Stock News HeadlinesCambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator ManufacturingDecember 5, 2024 | finance.yahoo.comSemi-Solid Dosage CDMO Market Report 2024-2030: The Lubrizol Corporation, Cambrex Corporation, and Contract Pharmaceuticals Dominate the Competitive LandscapeNovember 13, 2024 | globenewswire.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. April 2, 2025 | Paradigm Press (Ad)Cambrex Opens New Stability Storage Facility in Durham, North CarolinaOctober 17, 2024 | finance.yahoo.comCambrex Announces New Liquid-Phase Peptide Synthesis Manufacturing TechnologySeptember 19, 2024 | finance.yahoo.comFire, gas leak at Cambrex manufacturing facility, Triad officials sayJuly 31, 2024 | msn.comOne Equity Partners Invests in Italian Agricultural Tractor Attachment Manufacturer CBMMarch 27, 2024 | tmcnet.comChina CBM Group Co Ltd 08270March 19, 2024 | morningstar.comSee More Headlines CBM Stock Analysis - Frequently Asked Questions How were Cambrex's earnings last quarter? Cambrex Co. (NYSE:CBM) issued its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.05. The business's quarterly revenue was up 13.0% on a year-over-year basis. What other stocks do shareholders of Cambrex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cambrex investors own include Bristol-Myers Squibb (BMY), Illumina (ILMN), AbbVie (ABBV), Meta Platforms (META), CVS Health (CVS), Gilead Sciences (GILD) and NVIDIA (NVDA). Company Calendar Last Earnings8/02/2018Today4/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical Preparations Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CBM CIK820081 Webwww.cambrex.com Phone201-804-3000FaxN/AEmployees1,732Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$2.77 Trailing P/E Ratio21.66 Forward P/E RatioN/A P/E GrowthN/ANet Income$92.41 million Net Margins5.96% Pretax MarginN/A Return on Equity5.38% Return on Assets2.50% Debt Debt-to-Equity Ratio0.76 Current Ratio2.37 Quick Ratio1.70 Sales & Book Value Annual Sales$532.09 million Price / Sales3.80 Cash Flow$3.91 per share Price / Cash Flow15.36 Book Value$19.48 per share Price / Book3.08Miscellaneous Outstanding Shares33,720,000Free FloatN/AMarket Cap$2.02 billion OptionableOptionable Beta2.14 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NYSE:CBM) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambrex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cambrex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.